Sarepta Therapeutics (SRPT) Work In Process (2022 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Work In Process of $981.0 million for Q1 2026, up 28.71% year-over-year from $762.2 million in Q1 2025, and up 9.9% quarter-over-quarter from $892.7 million in Q4 2025.
Sarepta Therapeutics (SRPT) Work In Process (2022 - 2026) Analysis & Trends
Sarepta Therapeutics' Work In Process history runs 5 years deep, the most recent figure standing at $981.0 million for Q1 2026.
- In Q1 2026, Work In Process rose 28.71% year-over-year to $981.0 million; the TTM figure through Mar 2026 stood at $981.0 million (up 28.71% YoY), while the FY2025 annual figure was $892.7 million, up 46.18% from the prior year.
- Work In Process for Q1 2026 stood at $981.0 million, up from $892.7 million in the prior quarter.
- The five-year high for Work In Process was $981.0 million in Q1 2026, with the low at $269.2 million in Q4 2022.
- The 5-year median for Work In Process is $686.5 million (2024), against an average of $647.5 million.
- The sharpest annual moves came in 2023 and 2024: Work In Process increased 18.3% in 2023, then jumped 91.77% in 2024.
- Sarepta Therapeutics' Work In Process stood at $269.2 million in 2022, then gained by 18.3% to $318.5 million in 2023, then surged by 91.77% to $610.7 million in 2024, then jumped by 46.18% to $892.7 million in 2025, then rose by 9.9% to $981.0 million in 2026.
- Business Quant data shows SRPT's Work In Process at $981.0 million in Q1 2026, $892.7 million in Q4 2025, and $885.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 946.65 Mn |
| Mar 31, 2026 | 981.04 Mn |
| Dec 31, 2025 | 892.69 Mn |
| Sep 30, 2025 | 885.42 Mn |
| Jun 30, 2025 | 802.87 Mn |
| Mar 31, 2025 | 762.23 Mn |
| Dec 31, 2024 | 610.69 Mn |
| Sep 30, 2024 | 482.17 Mn |
| Jun 30, 2024 | 470.38 Mn |
| Dec 31, 2023 | 318.46 Mn |
| Dec 31, 2022 | 269.19 Mn |